The company said, “The Company is well funded with a strong cash and cash equivalent, and term deposit balance as at 30 September 2025 of approximately A$109.85M, which is in line with budget as at the beginning of FY2026, while progressing our clinical programs within announced timeframes. The total balance consists of: a cash and cash equivalent balance of A$83.41M and bank term deposits totaling A$26.44M, which have been recognised as short-term investments due to having maturities of more than 3 months and less than 12 months.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
- Immutep Showcases Promising Lung Cancer Treatment Results at ESMO Congress 2025
- Immutep Announces Breakthrough Results in Soft Tissue Sarcoma Trial
- Immutep presents two posters at ESMO on changing landscape for 1L NSCLC
- Immutep announces Phase II study of eftilagimod alfa met primary endpoint
- Immutep Completes FDA Project Optimus, Advances Efti Trials